Kley in Davos

More than 2,500 participants from the worlds of business, politics, science and culture as well as representatives of international organizations attended the annual meeting of the World Economic Forum this week. Besides discussing topics that Merck KGaA, Darmstadt, Germany, can make a positive contribution to, CEO Karl-Ludwig Kley shared his views on current economic challenges and the future development of Merck KGaA, Darmstadt, Germany, in various media interviews.

Consumer Health Division Sparks Debate on the Future of the OTC Sector

November 28, 2014 – Our Consumer Health division hosted a top level debate on key future aspects of the OTC sector, in London. Featuring contributions from leading analysts, professional representatives and patient groups, the event combined the experience and views of Merck Consumer Health’s senior management team with external perspectives on the major pressures and influences facing the industry.

Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

November 17, 2014 – Merck KGaA, Darmstadt, Germany, and Pfizer entered into a global agreement to co-develop and co-commercialize our investigational anti-PD-L1 antibody as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.
As part of the agreement, Merck KGaA, Darmstadt, Germany, will co-promote Pfizer’s Xalkori, a medicine to treat non-small cell lung cancer, in the United States and several other key markets.

Access to Medicine Index: Merck KGaA, Darmstadt, Germany, in sixth place

Darmstadt, Germany, November 18, 2014 – Merck KGaA, Darmstadt, Germany, announced today that it now ranks sixth in the Access to Medicine Index published yesterday by the Access to Medicine Foundation. Merck KGaA, Darmstadt, Germany, has moved up two places compared to the 2012 ranking. This improvement underlines the company’s commitment to helping overcome barriers to access for underserved populations and communities in low- and middle-income countries as part of its corporate responsibility and sustainable business approach. Every two years, the Access to Medicine Index benchmarks the top pharmaceutical companies on activities and initiatives that are advancing access to medicines in developing countries.

Merck KGaA, Darmstadt, Germany, reports strong top-line growth in the third quarter

"We are gearing up for a strong finish in 2014. All our businesses are performing well and contributed to across-the-board growth in the third quarter," said Karl-Ludwig Kley, Chairman of the Executive Board of Merck KGaA, Darmstadt, Germany.

Displaying Futures – How displays influence architecture

Merck KGaA, Darmstadt, Germany, is holding its “Displaying Futures”’ symposium in Shanghai, China on November 6, 2014. Focusing on the theme “Building Innovation – Displaying Architecture”, experts will discuss questions concerning the impact of innovative display solutions on architecture as well as the life of the people therein. The Displaying Futures Shanghai symposium is the fourth in a series of annual symposia held since 2011, in which Merck KGaA, Darmstadt, Germany, has set out to explore new avenues through an inspiring exchange between designers, artists, communications experts, architects and scientists.


Media Services for the US and Canada – News starting 2013, Dates & Publications

Latest Press Releases
Andreas Stickler and Roman Morten Werth
Andreas Stickler and Roman Morten Werth
Merck KGaA, Darmstadt, Germany, Announces Personnel Changes in Finance Function
Darmstadt, Germany, January 30, 2015 – Merck KGaA, Darmstadt, Germany, today announced that Andreas Stickler (43) has been appointed as new Head of Controlling of the Healthcare Business Sector. Roman Morten Werth (38) will succeed Andreas Stickler in his current position as Head of Mergers & Acquisitions (M&A).
Kley in Davos
Kley in Davos
Davos, January 20, 2015 - CEO Karl-Ludwig Kley talking to CNBC Europe while being in Davos, participating in the World Economic Forum (WEF). Kley is discussing the current state of Europe and says, the lack of coordination and cohesion in European businesses is the current problem. Meanwhile political leaders need a wake-up call. He also sheds some light on our plans for 2015, a year he forecasts will see less pharmaceutical M&A activity than 2014.
Merck KGaA, Darmstadt, Germany Obtains US Antitrust Clearance for Acquisition of Sigma-Aldrich
Merck KGaA, Darmstadt, Germany Obtains US Antitrust Clearance for Acquisition of Sigma-Aldrich
Darmstadt, Germany, December 23, 2014 – Merck KGaA, Darmstadt, Germany today announced that it has obtained antitrust clearance from the United States Federal Trade Commission (FTC) for its planned acquisition of US-based life science company Sigma-Aldrich.


Read how Merck KGaA, Darmstadt, Germany, and its affiliates are covered by media outlets around the world


Download Library
Download images, Media Kits and other material from our media download library


Calendar of Events
Find and register for upcoming events


Publication of Merck KGaA, Darmstadt, Germany.
In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate under the umbrella brand EMD.


Media Team
Merck KGaA 
Frankfurter Straße 250 
64293 Darmstadt 
Tel.: +49 6151 72-5000
Fax: +49 6151 72-3138


Communications Center
Tel.: +49 6151 72-0
Fax: +49 6151 72-2000


2nd quarter 2014Merck Interim Report
Merck on Facebook
Merck on Twitter
Read more on M - The Explorer Magazine

Using hamster cells to fight multiple sclerosis

Michel Revel has developed the multiple sclerosis drug Rebif®. He has dedicated his entire career as a researcher to the search for MS treatments.

Read more on M - The Explorer Magazine
Read more on M - The Explorer Magazine

The car couturier shows his passion for color

The technology visionary Rainer Buchmann enhances automobiles with pearl luster effect paints containing pigments from our company.

Read more on M - The Explorer Magazine